Stock Market Impact: Shares rose approximately 16% in pre‑market trading following the announcement.
Listed Companies and Sectors: Apogee Therapeutics (Biotechnology) entered a financing collaboration with Blackstone Life Sciences to develop and commercialise zumilokibart, a treatment for atopic dermatitis.
Investment Flows: The deal provides up to $1.3 billion – $800 million in synthetic royalty funding and $500 million in senior corporate debt – payable in tranches linked to Phase 3 enrollment ($100 million at signing, $100 million upon Phase 3 enrollment completion, $200 million upon positive Phase 3 data) and an additional $400 million upon FDA approval (with $150 million at Apogee’s option).
Royalty Terms: Blackstone will receive low‑to‑mid single‑digit tiered royalties on worldwide annual sales of zumilokibart for 15 years, with no royalties on sales exceeding $8 billion.
Cash Position & Guidance: Combined with Apogee’s existing cash of $1.3 billion, the financing positions the company to achieve financial sustainability through zumilokibart commercialization without requiring future equity financing; the company removed its previous cash‑runway guidance.
Interest Rates, Inflation, Liquidity, Fiscal/Monetary Policy: No related information disclosed.
